VentiV Scientific has secured FDA clearance for its advanced Mechanical Thrombectomy system featuring the new VentiV Pulse platform, a technological development that promises to enhance clinical capabilities in removing blood clots across various vascular conditions. Thrombectomy procedures are critical medical interventions that can mitigate patient suffering, reduce disability risks, and potentially save lives, particularly in treating conditions such as acute myocardial infarction, acute ischemic stroke, peripheral arterial disease, acute limb ischemia, and deep vein thrombosis.
According to Dan Ryan, a member of VentiV Scientific's Board of Directors, the new system addresses significant limitations in existing thrombectomy technologies. Traditional electric pump-based systems can unexpectedly clog and remove substantial blood volumes before effectively eliminating blood clots. The Pulse platform is engineered to provide more precise control, with the ability to instantly start, stop, and modulate thrombectomy force at the catheter tip. During typical thrombectomy procedures, clinicians navigate catheters through femoral arteries or veins to locate and remove blood clots, a process involving complex variables including clot age, size, location, and catheter specifications.
The VentiV system includes eighteen large-lumen catheter systems designed to address diverse clinical needs and potentially reduce procedural costs. The FDA clearance represents a significant advancement in medical device technology, offering healthcare professionals more nuanced tools for treating complex vascular conditions. By providing enhanced control and potentially reducing blood loss, the VentiV Mechanical Thrombectomy system could represent a meaningful improvement in patient care and surgical outcomes. The system's development reflects ongoing innovation in medical technology aimed at addressing clinical challenges in vascular interventions.
